Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 26;14(9):636. doi: 10.1038/s41419-023-06053-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — A Gating strategy of different immune cells. B The proportions of different immune cells in the SCLC-Y group (DMS114 and H2286) and the SCLC-A/N/P group (SHP77, H446, and H526). C MFI of Fas in CD45+ immune cells and CD45 + CD3 + T cells in five coculture groups (tumor cells and PBMCs). D MFI of Ki67 in different immune cells in two coculture systems of SCLC-Y cells and PBMCs after verteporfin exposure. E MFI of Fas in CD45+ immune cells and CD45 + CD3 + T cells in two SCLC-Y and PBMCs coculture systems after verteporfin exposure. F The proportions of Granzyme-B+ immune cells and activated T cells (CD45 + CD3 + HLA-DR + ) in two coculture systems of SCLC-Y cells and PBMCs after verteporfin exposure. SCLC small cell lung cancer, MFI median fluorescence intensity, PBMCs peripheral blood mononuclear cells.